Rigel Pharmaceuticals (RIGL) Stock Price, Quote & News

Company Profile

Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (I...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 624 1100

Fax: 650 624 1101

Website: www.rigel.com

Address:

611 Gateway Boulevard, Suite 900, South San Francisco, United States

GO_DAWGS Jul. 4 at 3:22 PM

$RIGL $UAMY $SRFM OT: Happy 4th all. Watching those jets burn JP-8 across the DC sky yesterday should make everyone proud and appreciate the freedoms we have. Many are deployed protecting us as we bbq and celebrate today. Think of them and their families and the sacrifices they make.

0 · Reply

tobeme100 Jul. 3 at 9:38 PM

$RIGL mgt team believes Hannah’s oncology background will make her central to maximizing VEPPANU’s long‑term value. VEPPANU’s long‑term valuation depends heavily on clinical expansion, not just the initial label. Hannah is placed into CMO who will shape that trajectory. Just a thought.

2 · Reply

GO_DAWGS Jul. 3 at 8:40 PM

$RIGL waiting on the “Paul Harvey” for this CMO change!!!

0 · Reply

dark_gamma Jul. 3 at 4:32 PM

$RIGL Options Heatmap - Key Levels Update Last: $38.72 Key Resistance: $39.11 ($2.0M) Key Support: $38.69 ($11.8M) | $38.29 ($2.0M) | $37.00 ($1.6M) Stay ahead of market movements with our daily updates on key levels. #RIGL #Options #Trading #GEX #GammaExposure

2 · Reply

Tetoooo Jul. 3 at 2:57 PM

$RIGL based on http://FinPile.ai I am adding this to my portfolio

0 · Reply

DBales26 Jul. 3 at 2:28 PM

$RIGL Does anybody think it's odd that Rigel appointed Hannah As their new CMO after recent proxy voting in May showed about 1.5M shares withheld and voted against her to remain on the Bord of Directors? If just over 14% of the total votes from shareholders that actually cast votes (~10.7M, not including broker non-votes) didn't want her to remain then why even add her as CMO and not start an executive search for a new CMO, similar to when Wolfgang left? Potential strategic transaction coming up?

2 · Reply

MaxKlim Jul. 3 at 2:18 PM

$RIGL in August ! 80 $ EoY !!!

0 · Reply

mikesterz7 Jul. 3 at 2:17 PM

$RIGL $50 soon

0 · Reply

ZamieRichie Jul. 3 at 2:06 PM

HAPPY CANADA DAY WEEK AND INDEPENDENCE DAY WEEKEND. But this is bigger than flags and fireworks. Canada and the US both need secure access to critical minerals. That is why I keep watching $NRED First people see the copper-gold story. Then they see Wilmac in British Columbia. Then someone points out the real part: NovaRed added Kristi L. Noem as a strategic advisor. Former U.S. Secretary of Homeland Security. Former Governor. A policy and national-security voice tied directly to critical minerals, infrastructure and supply-chain resilience. MetalCore gives the AI-mineral intelligence angle. Kristi Noem gives the critical-minerals policy / security / supply-chain angle. This is how a junior copper-gold story starts getting discovered before the crowd fully understands it $RIGL

0 · Reply

Breton2018 Jul. 3 at 2:00 PM

$RIGL

0 · Reply

Rigel appoints Alison Hannah as Chief Medical Officer and Vice President

Jul 1, 2026, 8:05 AM EDT - 3 days ago

Rigel Appoints Board Member Alison L. Hannah, M.D.

2026-06-16T20:13:09.000Z - 18 days ago

Rigel closes license agreement for Veppanu

ARVN PFE

Jun 16, 2026, 4:01 PM EDT - 18 days ago

Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)

Jun 16, 2026, 7:00 AM EDT - 18 days ago

Rigel Pharmaceuticals Slides: Corporate presentation

Jun 3, 2026, 8:45 AM EDT - 4 weeks ago

Rigel Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026

May 27, 2026, 8:05 AM EDT - 5 weeks ago

Rigel to Present at the Jefferies Global Healthcare Conference

May 21, 2026, 5:17 PM EDT - 6 weeks ago

Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress

May 19, 2026, 9:30 AM EDT - 6 weeks ago

Rigel Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 14, 2026, 8:05 AM EDT - 7 weeks ago

Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference

2026-05-13T09:58:10.000Z - 7 weeks ago

Rigel Pharmaceuticals price target raised to $81 from $69 at Citi

2026-05-12T17:45:03.000Z - 7 weeks ago

H.C. Wainwright says Pfizer handing off Veppanu to Rigel ‘makes strategic sense’

ARVN PFE

2026-05-12T16:35:26.000Z - 7 weeks ago

Arvinas, Pfizer enter license pact with Rigel Pharmaceuticals for Veppanu

ARVN PFE

2026-05-12T13:02:04.000Z - 7 weeks ago

Rigel Pharmaceuticals enters license agreement with Arvinas, Pfizer

ARVN PFE

May 12, 2026, 8:00 AM EDT - 7 weeks ago

Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug

ARVN PFE

May 12, 2026, 8:00 AM EDT - 7 weeks ago

Rigel Pharmaceuticals Transcript: Investor update

May 12, 2026, 8:00 AM EDT - 7 weeks ago

Rigel Pharmaceuticals Press release: Investor update

May 12, 2026, 7:00 AM EDT - 7 weeks ago

Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer

May 12, 2026, 2:00 AM EDT - 7 weeks ago

Rigel Pharmaceuticals Slides: Corporate presentation

2026-05-07T10:45:47.000Z - 2 months ago

Rigel Pharmaceuticals price target lowered to $69 from $71 at Citi

May 5, 2026, 4:30 PM EDT - 2 months ago

Rigel Pharmaceuticals Earnings Call Transcript: Q1 2026

May 5, 2026, 4:30 PM EDT - 2 months ago

Rigel Pharmaceuticals Quarterly report: Q1 2026

May 5, 2026, 4:30 PM EDT - 2 months ago

Rigel Pharmaceuticals Earnings release: Q1 2026

May 5, 2026, 4:30 PM EDT - 2 months ago

Rigel Pharmaceuticals Slides: Q1 2026

2026-05-05T20:07:48.000Z - 2 months ago

Rigel Pharmaceuticals reports Q1 EPS 44c, consensus 87c

May 5, 2026, 4:01 PM EDT - 2 months ago

Rigel Reports First Quarter 2026 Financial Results

May 5, 2026, 7:00 AM EDT - 2 months ago

Rigel Pharmaceuticals Slides: Corporate presentation

Apr 28, 2026, 8:05 AM EDT - 2 months ago

Rigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial Results

Apr 7, 2026, 8:05 AM EDT - 3 months ago

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Apr 3, 2026, 8:00 AM EDT - 3 months ago

Rigel Pharmaceuticals Proxy statement: Proxy filing

Apr 3, 2026, 8:00 AM EDT - 3 months ago

Rigel Pharmaceuticals Proxy statement: Proxy filing

2026-03-31T12:14:46.000Z - 3 months ago

Rigel Pharmaceuticals’ pralsetinib shows efficacy in NSCLC clinical trial

Mar 31, 2026, 8:05 AM EDT - 3 months ago

Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology

Mar 3, 2026, 4:30 PM EST - 4 months ago

Rigel Pharmaceuticals Earnings Call Transcript: Q4 2025

Mar 3, 2026, 4:30 PM EST - 4 months ago

Rigel Pharmaceuticals Annual report: Q4 2025

Mar 3, 2026, 4:30 PM EST - 4 months ago

Rigel Pharmaceuticals Earnings release: Q4 2025

Mar 3, 2026, 4:30 PM EST - 4 months ago

Rigel Pharmaceuticals Slides: Q4 2025

2026-03-03T21:15:06.000Z - 4 months ago

Rigel Pharmaceuticals sees FY26 revenue $275M-$290M, consensus $279.31M

2026-03-03T21:05:15.000Z - 4 months ago

Rigel Pharmaceuticals reports Q4 EPS $13.54 with items, consensus $1.20

Mar 3, 2026, 4:01 PM EST - 4 months ago

Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 24, 2026, 8:05 AM EST - 4 months ago

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update

Feb 3, 2026, 8:05 AM EST - 5 months ago

Rigel Appoints Michael P. Miller to the Board of Directors

Jan 14, 2026, 6:00 PM EST - 6 months ago

Rigel Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

2026-01-14T10:45:17.000Z - 6 months ago

Rigel Pharmaceuticals price target raised to $71 from $69 at Citi

2026-01-12T13:11:10.000Z - 6 months ago

Rigel Pharmaceuticals sees Q4 revenue $69.8M, consensus $66.44M

2026-01-12T13:10:46.000Z - 6 months ago

Rigel Pharmaceuticals sees FY26 revenue $275M-$290M, consensus $291.58M

Jan 12, 2026, 8:05 AM EST - 6 months ago

Rigel Provides Business Update and 2026 Outlook

Jan 12, 2026, 7:00 AM EST - 6 months ago

Rigel Pharmaceuticals Slides: Corporate presentation

Jan 7, 2026, 8:05 AM EST - 6 months ago

Rigel to Present at the 44th Annual J.P. Morgan Healthcare Conference

2025-12-07T17:50:04.000Z - 7 months ago

Rigel Pharmaceuticals announces updated data from Phase 1b study of R2891

Dec 7, 2025, 9:30 AM EST - 7 months ago

Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition

Dec 7, 2025, 7:00 AM EST - 7 months ago

Rigel Pharmaceuticals Slides: Corporate Presentation

Dec 3, 2025, 8:30 AM EST - 7 months ago

Rigel Pharmaceuticals Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 26, 2025, 8:05 AM EST - 7 months ago

Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 18, 2025, 5:00 AM EST - 8 months ago

Rigel Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025

Nov 17, 2025, 8:05 AM EST - 8 months ago

Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology

Nov 12, 2025, 8:05 AM EST - 8 months ago

Rigel to Present at the Jefferies Global Healthcare Conference in London

Nov 4, 2025, 4:30 PM EST - 8 months ago

Rigel Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 4, 2025, 4:30 PM EST - 8 months ago

Rigel Pharmaceuticals Earnings release: Q3 2025

Nov 4, 2025, 4:30 PM EST - 8 months ago

Rigel Pharmaceuticals Quarterly report: Q3 2025

Nov 4, 2025, 4:30 PM EST - 8 months ago

Rigel Pharmaceuticals Slides: Q3 2025

Nov 4, 2025, 4:01 PM EST - 8 months ago

Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 3, 2025, 9:05 AM EST - 8 months ago

Rigel Announces One Oral and Four Poster Presentations at the 67th American Society of Hematology Annual Meeting and Exposition

Oct 30, 2025, 2:20 PM EDT - 8 months ago

This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is 'growing substantially'

Oct 29, 2025, 8:05 AM EDT - 8 months ago

Rigel Announces Conference Call and Webcast to Report Third Quarter 2025 Financial Results and Business Update

Oct 8, 2025, 8:05 AM EDT - 9 months ago

Rigel Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in Patients with Lower-Risk MDS

Sep 9, 2025, 1:30 PM EDT - 10 months ago

Rigel Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 8:35 AM EDT - 10 months ago

Rigel Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Aug 26, 2025, 8:05 AM EDT - 11 months ago

Rigel to Participate in Upcoming September Investor Conferences

Aug 15, 2025, 5:20 PM EDT - 11 months ago

Overlooked Stock: RIGL Nearly Doubles Stock in August

Aug 15, 2025, 12:00 PM EDT - 11 months ago

The Big 3: OPEN, RIGL, JOBY

JOBY OPEN

Aug 5, 2025, 4:30 PM EDT - 11 months ago

Rigel Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 11 months ago

Rigel Pharmaceuticals Quarterly report: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 11 months ago

Rigel Pharmaceuticals Earnings release: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 11 months ago

Rigel Pharmaceuticals Slides: Q2 2025

Aug 5, 2025, 4:01 PM EDT - 11 months ago

Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 29, 2025, 8:05 AM EDT - 1 year ago

Rigel Announces Conference Call and Webcast to Report Second Quarter 2025 Financial Results and Business Update

Jun 4, 2025, 12:50 PM EDT - 1 year ago

Rigel Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

May 22, 2025, 5:20 PM EDT - 1 year ago

Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress

May 6, 2025, 4:30 PM EDT - 1 year ago

Rigel Pharmaceuticals Earnings Call Transcript: Q1 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

Rigel Pharmaceuticals Earnings release: Q1 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

Rigel Pharmaceuticals Quarterly report: Q1 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

Rigel Pharmaceuticals Slides: Q1 2025

May 6, 2025, 4:01 PM EDT - 1 year ago

Rigel Reports First Quarter 2025 Financial Results and Provides Business Update

May 6, 2025, 7:00 AM EDT - 1 year ago

Rigel Pharmaceuticals Slides: Investor Presentation

Apr 29, 2025, 8:05 AM EDT - 1 year ago

Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Rigel Pharmaceuticals Proxy statement: Proxy Filing

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Rigel Pharmaceuticals Proxy statement: Proxy Filing

Mar 27, 2025, 8:05 AM EDT - 1 year ago

Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation

Mar 10, 2025, 8:05 AM EDT - 1 year ago

Rigel Appoints Mark W. Frohlich, M.D.

Mar 4, 2025, 4:30 PM EST - 1 year ago

Rigel Pharmaceuticals Earnings Call Transcript: Q4 2024

Mar 4, 2025, 4:30 PM EST - 1 year ago

Rigel Pharmaceuticals Earnings release: Q4 2024

Mar 4, 2025, 4:30 PM EST - 1 year ago

Rigel Pharmaceuticals Annual report: Q4 2024

Mar 4, 2025, 4:30 PM EST - 1 year ago

Rigel Pharmaceuticals Slides: Q4 2024

Mar 4, 2025, 4:01 PM EST - 1 year ago

Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 25, 2025, 8:05 AM EST - 1 year ago

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update

Jan 22, 2025, 8:05 AM EST - 1 year ago

Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease

Jan 16, 2025, 11:15 AM EST - 1 year ago

Rigel Pharmaceuticals Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 16, 2025, 11:15 AM EST - 1 year ago

Rigel Pharmaceuticals Slides: FY 2025

Jan 13, 2025, 8:05 AM EST - 1 year ago

Rigel Provides Business Update and 2025 Outlook

Jan 9, 2025, 8:05 AM EST - 1 year ago

Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS

Jan 8, 2025, 8:05 AM EST - 1 year ago

Rigel to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 9, 2024, 12:02 PM EST - 1 year ago

Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition

Dec 2, 2024, 8:05 AM EST - 1 year ago

Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS

Nov 19, 2024, 4:30 AM EST - 1 year ago

Rigel Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2024

Nov 12, 2024, 8:05 AM EST - 1 year ago

Rigel to Present at the Jefferies London Healthcare Conference

Nov 7, 2024, 4:30 PM EST - 1 year ago

Rigel Pharmaceuticals Earnings Call Transcript: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

Rigel Pharmaceuticals Earnings release: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

Rigel Pharmaceuticals Quarterly report: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

Rigel Pharmaceuticals Slides: Q3 2024

Nov 7, 2024, 4:01 PM EST - 1 year ago

Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 5, 2024, 9:05 AM EST - 1 year ago

Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition

Oct 31, 2024, 8:05 AM EDT - 1 year ago

Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update

Oct 24, 2024, 4:35 PM EDT - 1 year ago

Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for GAVRETO® (pralsetinib)

Oct 16, 2024, 10:00 AM EDT - 1 year ago

Optime Care Expands Partnership with Rigel Pharmaceuticals to Include Commercial Distribution for TAVALISSE®

Oct 4, 2024, 8:05 AM EDT - 1 year ago

Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GO_DAWGS Jul. 4 at 3:22 PM

0 · Reply

tobeme100 Jul. 3 at 9:38 PM

2 · Reply

GO_DAWGS Jul. 3 at 8:40 PM

$RIGL waiting on the “Paul Harvey” for this CMO change!!!

0 · Reply

dark_gamma Jul. 3 at 4:32 PM

2 · Reply

Tetoooo Jul. 3 at 2:57 PM

$RIGL based on http://FinPile.ai I am adding this to my portfolio

0 · Reply

DBales26 Jul. 3 at 2:28 PM

2 · Reply

MaxKlim Jul. 3 at 2:18 PM

$RIGL in August ! 80 $ EoY !!!

0 · Reply

mikesterz7 Jul. 3 at 2:17 PM

$RIGL $50 soon

0 · Reply

ZamieRichie Jul. 3 at 2:06 PM

0 · Reply

Breton2018 Jul. 3 at 2:00 PM

$RIGL

0 · Reply

MaxKlim Jul. 3 at 1:38 PM

$RIGL https://clinicaltrials.gov/study/NCT07304011

0 · Reply

MaxKlim Jul. 3 at 1:37 PM

$RIGL https://pubmed.ncbi.nlm.nih.gov/42381267/

0 · Reply

MaxKlim Jul. 3 at 1:36 PM

$RIGL https://pubmed.ncbi.nlm.nih.gov/42382470/

0 · Reply

joNANOthan Jul. 2 at 8:04 PM

$RIGL Grabbed some more today. Poor shorts.

0 · Reply

christopher18 Jul. 2 at 7:16 PM

$RIGL It's crazy how a $2 gain sold off in two hours this morning. WOW!

1 · Reply

MaxKlim Jul. 2 at 6:52 PM

$RIGL Today, the bears held the $40 level.

1 · Reply

MaxKlim Jul. 2 at 1:26 PM

$RIGL What are everyone's forecasts for Q2 revenue and profit? In a month, we'll see who came closest to reality. My forecast: revenue of 72–75 million, profit of 30–31 million.

1 · Reply

MaxKlim Jul. 2 at 11:05 AM

$RIGL 1$

0 · Reply

Estimize Jul. 2 at 11:03 AM

Wall St is expecting 0.13 EPS for $RIGL Q2 [Reporting 08/04 AMC] http://www.estimize.com/intro/rigl?chart=historical&metric_name=eps&utm_co

0 · Reply

Berakhot Jul. 1 at 10:18 PM

$RIGL Dr Hannah... Career Highlights Current Role: Appointed Executive Vice President and Chief Medical Officer at Rigel Pharmaceuticals in July 2026, succeeding Lisa Rojkjaer, M.D. BioSpace Previous Executive Role: Chief Medical Officer at CytomX Therapeutics (Feb 2020–Sep 2022). Consulting Experience: Over 25 years as an oncology clinical trial consultant, working with nearly 30 pharmaceutical and biotech companies, including Onyx Pharmaceuticals, Kosan, and SUGEN (acquired by Pfizer) ----- V ----- Regulatory Expertise: Has successfully filed over 40 First-in-Human regulatory applications and contributed to the marketing approval of multiple anticancer therapeutics, such as talazoparib, enzalutamide, defibrotide, carfilzomib, sunitinib, toceranib, and others The Org. https://www.gurufocus.com/news/8941565/rigel-pharmaceuticals-appoints-dr-alison-l-hannah-as-cmo-rigl

1 · Reply

Gabriel1234 Jul. 1 at 10:06 PM

$RIGL https://www.tipranks.com/news/company-announcements/rigel-appoints-alison-hannah-as-new-chief-medical-officer?mod=mw_quote_news

0 · Reply

biid Jul. 1 at 9:53 PM

$RIGL If Lisa Rojkjaer is indeed retiring, I wish her well. If she's going to, in some capacity, remain with the organization (e.g. on the BoD), that's cool as well. Here are a few quotes from one of today's news releases: Raul Rodriguez: "[Hannah's] deep experience leading oncology clinical development and advancing investigational therapies through the regulatory process will be extremely valuable as we continue to advance our development pipeline, including R289 in lower-risk MDS, vepdegestrant in metastatic breast cancer and other potential opportunities." Alison Hannah: "I look forward to working closely with the leadership team to help guide the continued development of R289 and Rigel's broader clinical strategy, including the recent addition of vepdegestrant." Based on the above, I learned today that vepdegestrant (VEPPANU) will not only contribute to their product mix but also their pipeline in other indication(s). Excellent news! https://www.prnewswire.com/news-releases/rigel-appoints-board-member-alison-l-hannah-md-as-chief-medical-officer-302815365.html

0 · Reply

Market Cap	716.40M
Revenue (ttm)	294.28M
Net Income (ttm)	367.02M
EPS (ttm)	N/A
PE Ratio	6.06
Forward PE	10.91
Profit Margin	124.72%
Debt to Equity Ratio	0.04

Volume	573,900
Avg Vol	400,094
Day's Range	N/A - N/A
Shares Out	18.50M
Stochastic %K	76%
Beta	1.14
Analysts	Sell
Price Target	$54.20